Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 1-(5'-hydroxyhexyl)-3,7-dimethylxanthine
2. 1-(5r-hydroxyhexyl)-3,7-dimethylxanthine
3. 3,7-dimethyl-1-(5-hydroxyhexyl)xanthine
4. A-802710
5. Bl 194
6. Ct-1501r
1. (r)-lisofylline
2. 100324-81-0
3. Protec
4. Ct 1501r
5. Ct-1501r
6. Lisophylline
7. 1-[(5r)-5-hydroxyhexyl]-3,7-dimethylpurine-2,6-dione
8. Lisofylline, (r)-
9. (r)-lisophylline
10. 3,7-dihydro-1-[(5r)-5-hydroxyhexyl]-3,7-dimethyl-1h-purine-2,6-dione
11. 1-((r)-5-hydroxyhexyl)theobromine
12. 1-[(r)-5-hydroxyhexyl]theobromine
13. Lisofilina
14. Lisofyllinum
15. L1f2q2x956
16. (-)-lisofylline
17. 1-(5r-hydroxyhexyl)-3,7-dimethylxanthine
18. Protec (tn)
19. Lisofylline [mi]
20. Lisofylline [inn]
21. Lisofylline (usan/inn)
22. Lisofylline [usan]
23. Chembl1411
24. Schembl39131
25. (r)-lsf
26. Lisofylline [who-dd]
27. Gtpl9225
28. Dtxsid7058709
29. Ct1501r
30. 1h-purine-2,6-dione, 3,7-dihydro-1-(5-hydroxyhexyl)-3,7-dimethyl-, (r)-
31. Chebi:143527
32. Ex-a6722
33. Zinc1887263
34. Akos025394050
35. Db12406
36. Hy-109854a
37. Ncgc00186630-01
38. 1-(5-r-hydroxyhexyl)-3,7-dimethylxanthine
39. Cs-0034091
40. R-1-(5-hydroxyhexyl)-3,7-dimethylxanthine
41. (r)-1-(5-hydroxyhexyl)-3,7-dimethylxanthine
42. D04748
43. J-000102
44. Q15409404
45. 1-[(5r)-5-hydroxyhexyl]-3,7-dimethyl-purine-2,6-dione
46. (r)-1-(5-hydroxyhexyl)-3,7-dimethyl-1h-purine-2,6(3h,7h)-dione
47. 1-[(5r)-5-hydroxyhexyl]-3,7-dimethyl-3,7-dihydro-1h-purine-2,6-dione
48. 1-[(5r)-5-hydroxyhexyl]-3,7-dimethyl-2,3,6,7-tetrahydro-1h-purine-2,6-dione
| Molecular Weight | 280.32 g/mol |
|---|---|
| Molecular Formula | C13H20N4O3 |
| XLogP3 | 0.7 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 5 |
| Exact Mass | 280.15354051 g/mol |
| Monoisotopic Mass | 280.15354051 g/mol |
| Topological Polar Surface Area | 78.7 Ų |
| Heavy Atom Count | 20 |
| Formal Charge | 0 |
| Complexity | 390 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Adjuvants, Immunologic
Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. (See all compounds classified as Adjuvants, Immunologic.)
Radiation-Sensitizing Agents
Drugs used to potentiate the effectiveness of radiation therapy in destroying unwanted cells. (See all compounds classified as Radiation-Sensitizing Agents.)
Anti-Inflammatory Agents, Non-Steroidal
Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)
Immunosuppressive Agents
Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. (See all compounds classified as Immunosuppressive Agents.)
Lisofylline has known human metabolites that include lisofylline 4,5-diol and pentoxifylline.
S73 | METXBIODB | Metabolite Reaction Database from BioTransformer | DOI:10.5281/zenodo.4056560
ABOUT THIS PAGE
A Lisofylline manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Lisofylline, including repackagers and relabelers. The FDA regulates Lisofylline manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Lisofylline API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Lisofylline supplier is an individual or a company that provides Lisofylline active pharmaceutical ingredient (API) or Lisofylline finished formulations upon request. The Lisofylline suppliers may include Lisofylline API manufacturers, exporters, distributors and traders.
Lisofylline Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Lisofylline GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Lisofylline GMP manufacturer or Lisofylline GMP API supplier for your needs.
A Lisofylline CoA (Certificate of Analysis) is a formal document that attests to Lisofylline's compliance with Lisofylline specifications and serves as a tool for batch-level quality control.
Lisofylline CoA mostly includes findings from lab analyses of a specific batch. For each Lisofylline CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Lisofylline may be tested according to a variety of international standards, such as European Pharmacopoeia (Lisofylline EP), Lisofylline JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Lisofylline USP).
LOOKING FOR A SUPPLIER?
